Safety Profile
Known Safety Concerns
- FATAL apnoea/laryngospasm in infants/young children — CONTRAINDICATED under 2 years topically and orally; CYP3A4 inhibition (drug interactions); G6PD deficiency haemolysis; hepatotoxicity at high doses
Contraindications
- FATAL apnoea/laryngospasm in infants/young children — CONTRAINDICATED under 2 years topically and orally; CYP3A4 inhibition (drug interactions); G6PD deficiency haemolysis; hepatotoxicity at high doses
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Peppermint essential oil is steam-distilled from Mentha piperita leaves, standardised to contain 40–55% menthol, 15–25% menthone, menthyl acetate, 1,8-cineole, and limonene. Clinically established applications: enteric-coated peppermint oil capsules for IBS (irritable bowel syndrome) — Level A evidence (Cochrane review: NNT ~2.5 for global symptom reduction); topical application for tension headache (comparable to paracetamol in RCTs); inhaled for nausea. Topical: cooling, analgesic, mild local anaesthetic (TRPM8 channel agonist). CRITICAL SAFETY — ORAL/TOPICAL USE IN INFANTS AND YOUNG CHILDREN: Menthol causes reflex apnoea (breathing cessation) and laryngospasm in infants and young children when applied to the face, nose, or chest — FATAL CASES documented. ABSOLUTE CONTRAINDICATION in infants under 2 years (topical and oral). European Medicines Agency (EMA): peppermint oil not for children under 8 years without medical supervision. Direct nasal application contraindicated in all ages. ORAL USE (concentrated EO): undiluted peppermint essential oil ingestion can cause heartburn, nausea, oesophageal sphincter relaxation, allergic reactions, and hepatotoxicity at high doses. Products providing 20–30 ml of essential oil solution for oral adult use are at doses far exceeding established safe therapeutic ranges. Drug interactions: CYP3A4 inhibition (menthol inhibits CYP3A4) — may increase plasma levels of many medications; caution with immunosuppressants, statins, anticoagulants. G6PD deficiency: menthol can cause haemolysis — contraindicated. Enteric-coated capsules (clinically studied form) are distinct from neat EO oral consumption.
Biological and Chemical Classification
- Scientific Name
- Mentha piperita
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- FATAL apnoea/laryngospasm in infants/young children — CONTRAINDICATED under 2 years topically and orally; CYP3A4 inhibition (drug interactions); G6PD deficiency haemolysis; hepatotoxicity at high doses
The available scientific evidence for Peppermint Essential Oil indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:08
Evidence Distribution
-
Observational / other LOW evidence YELLOWMitigation of salinity stress in Mentha piperita L. through foliar application of chitosan-salicylic acid encapsulated ZnO nanoparticles. ↗Al-Obaidi MHR et al.. Mitigation of salinity stress in Mentha piperita L. through foliar application of chitosan-salicylic acid encapsulated ZnO nanoparticles.. Sci Rep. 2026. PMID:41927725.PMID 41927725 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41927725/
-
Observational / other LOW evidence YELLOWPseudomonas fluorescens improves morph-physiological characteristics, essential oil compounds, and gene expression implicated in menthol biosynthesis under water stress conditions in peppermint. ↗Mohammed OA et al.. Pseudomonas fluorescens improves morph-physiological characteristics, essential oil compounds, and gene expression implicated in menthol biosynthesis under water stress conditions in peppermint.. Antonie Van Leeuwenhoek. 2026. PMID:41912996.PMID 41912996 ↗Journal Antonie Van LeeuwenhoekYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41912996/
-
Observational / other LOW evidence YELLOWDose-Dependent Cytotoxic Effects of Mentha piperita Essential Oil on A549 Human Lung Carcinoma Cells. ↗Turan B et al.. Dose-Dependent Cytotoxic Effects of Mentha piperita Essential Oil on A549 Human Lung Carcinoma Cells.. J Craniofac Surg. 2026. PMID:41842759.PMID 41842759 ↗Journal J Craniofac SurgYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41842759/
-
Observational / other LOW evidence YELLOWColletotrichum magnum Species Complex: Emerging Pathogens in Tropical and Subtropical Regions. ↗Wang SY et al.. Colletotrichum magnum Species Complex: Emerging Pathogens in Tropical and Subtropical Regions.. Phytopathology. 2026. PMID:41842601.PMID 41842601 ↗Journal PhytopathologyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41842601/
-
Observational / other LOW evidence YELLOWReduced geomagnetic field modulates photosynthetic electron flow, menthol yield, flavonoid photoprotection and ROS homeostasis in peppermint (Mentha u00d7 piperita L.). ↗Mannino G et al.. Reduced geomagnetic field modulates photosynthetic electron flow, menthol yield, flavonoid photoprotection and ROS homeostasis in peppermint (Mentha u00d7 piperita L.).. Plant Physiol Biochem. 2026. PMID:41831415.PMID 41831415 ↗Journal Plant Physiol BiochemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41831415/
-
Observational / other LOW evidence YELLOWNeuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment. ↗Oh KI et al.. Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment.. Int J Mol Sci. 2026. PMID:41828723.PMID 41828723 ↗Journal Int J Mol SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41828723/
-
Observational / other LOW evidence YELLOWTranscriptomic Insights Into Peppermint Adventitious Root Development Induced by Trichoderma Volatile Organic Compounds Under Salt Stress. ↗Zhao Z et al.. Transcriptomic Insights Into Peppermint Adventitious Root Development Induced by Trichoderma Volatile Organic Compounds Under Salt Stress.. Physiol Plant. 2026. PMID:41816833.PMID 41816833 ↗Journal Physiol PlantYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41816833/
-
Observational / other LOW evidence YELLOWPhytochemical Variability of Mentha L. Species Over Three Growing Seasons. ↗Pluhu00e1u010dkovu00e1 H et al.. Phytochemical Variability of Mentha L. Species Over Three Growing Seasons.. Chem Biodivers. 2026. PMID:41771816.PMID 41771816 ↗Journal Chem BiodiversYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41771816/
-
Observational / other LOW evidence YELLOWNanoformulation of peppermint (Mentha Piperita L.) and rosemary (Rosmarinus officinalis L.) essential oils: antibacterial effects. ↗Teimouri S et al.. Nanoformulation of peppermint (Mentha Piperita L.) and rosemary (Rosmarinus officinalis L.) essential oils: antibacterial effects.. Int Microbiol. 2026. PMID:41760823.PMID 41760823 ↗Journal Int MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41760823/
-
Observational / other LOW evidence YELLOWFumigant Toxicity of Essential Oils of the Lamiaceae Family Against Spodoptera frugiperda Larvae. ↗Ayala-Guerrero LM et al.. Fumigant Toxicity of Essential Oils of the Lamiaceae Family Against Spodoptera frugiperda Larvae.. Insects. 2026. PMID:41752565.PMID 41752565 ↗Journal InsectsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41752565/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Peppermint Essential Oil. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a high safety concern. Its use in dietary supplements is associated with documented adverse events.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the High classification for Peppermint Essential Oil
A score of 6.5 places this ingredient in the High band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.